SCHEMBL12296014

SCHEMBL12296014

[2H]C([2H])([2H])Oc1ccc(CCOC(=N)C(Cl)(Cl)Cl)cc1OC([2H])([2H])[2H]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.40
KMT2A Q03164 2/20 0.39
ATM Q13315 2/20 0.39
KDM4E B2RXH2 1/20 0.39
APP P05067 1/20 0.38
STAT3 P40763 1/20 0.38
POLB P06746 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
CA2 P00918 1/20 0.36
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
AOC3 Q16853 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12295983 0.97 MAPT (0.44) MAPTKMT2AATMKDM4EAPP
SCHEMBL12296002 0.97 MAPT (0.44) MAPTKMT2AATMKDM4EAPP
SCHEMBL1323237 0.90 MAPT (0.49) MAPTKMT2AATMKDM4EAPP
SCHEMBL12327945 0.80 HDAC1 (0.45) KMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL12328264 0.80 SIGMAR1 (0.46)
SCHEMBL2632438 0.80 MET (0.38) MAPTKMT2AATMKDM4EAPP
SCHEMBL16481554 0.80 CYP1A2 (0.54) KMT2AAPPCYP19A1CYP1A2CYP3A4
SCHEMBL2632620 0.80 CHRM5 (0.42) MAPTKMT2AATMKDM4EAPP
SCHEMBL13917147 0.80 MAPT (0.47) MAPTKMT2AATMKDM4ESTAT3
SCHEMBL12296056 0.78 BCHE (0.50) KMT2AKDM4EAPPCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022098-B2 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2011-09-20 US disclosed
US-20100152276-A1 DEUTERATED AMINOCYCLOHEXYL ETHER COMPOUNDS AND PROCESSES FOR PREPARING SAME CARDIOME PHARMA CORP. (CA) 2010-06-17 US disclosed
US-7705036-B2 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2010-04-27 US disclosed
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same DDC, HDHD5, DDT MAPT 3508/4885KMT2A 870/4885ATM 2258/4885
US-20100152276-A1 DEUTERATED AMINOCYCLOHEXYL ETHER COMPOUNDS AND PROCESSES FOR PREPARING SAME DDC, HDHD5, DDT MAPT 3508/4885KMT2A 870/4885ATM 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.